CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a clinical-stage biotherapeutic company with a market ...
Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection ... hematopoietic stem-cell transplant (HSCT) recipients, and patients receiving ...
Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s ...
Medpage Today on MSN20d
Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia"Without HSCT, people with TDT need blood transfusions and iron chelation ... and there will be all sorts of late infections.
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 ...
Theoretically, HSCT offers 2 major advantages in the treatment ... During the first part of this phase, the major problems encountered are infections from endogenous bacteria, the reactivation ...
Researchers sought to determine whether venetoclax plus decitabine would lead to enhanced feasibility for allogeneic HSCT in patients with AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback